Fabry Disease: More than a Phenocopy of Hypertrophic Cardiomyopathy.
Kamil StankowskiStefano FigliozziVincenzo BattagliaFederica CatapanoMarco FranconeLorenzo MontiPublished in: Journal of clinical medicine (2023)
Fabry disease (FD) is a genetic lysosomal storage disease with frequent cardiovascular involvement, whose presence is a major determinant of adverse clinical outcomes. As a potentially treatable cause of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction, the early recognition of FD is crucial to initiate enzyme replacement therapy and improve long-term prognosis. Multimodality imaging plays a central role in the evaluation of patients with FD and helps in the differential diagnosis of other conditions presenting with LVH. In the present review, we explore the current applications of multimodality cardiac imaging, in particular echocardiography and cardiovascular magnetic resonance, in the diagnosis, prognostic assessment, and follow-up of patients with FD.
Keyphrases
- hypertrophic cardiomyopathy
- left ventricular
- replacement therapy
- magnetic resonance
- high resolution
- acute myocardial infarction
- cardiac resynchronization therapy
- heart failure
- aortic stenosis
- left atrial
- mitral valve
- gene expression
- computed tomography
- emergency department
- coronary artery disease
- mass spectrometry
- atrial fibrillation
- case report
- percutaneous coronary intervention
- transcatheter aortic valve replacement
- aortic valve
- adverse drug